https://www.acumenresearchandconsulting.com/
Home Services Industry Services Press Releases About Us Blogs Report Store Contact us

Femtech Market Size

Published : May 2022

Report ID: ARC2893

Pages : 250

Format : Femtech Market Size

The global femtech market size accounted for US$ 25,291 Mn in 2021 and is estimated to reach US$ 97,317 Mn by 2030, with a significant CAGR of 16.3% from 2022 to 2030.

Femtech refers to technology-enabled software, diagnostics, products, and services that benefit women's health. In 2016, Ida Tin, the founder of Clue, a mobile fertility tracking software, coined the term "femtech." Femtech is a movement to create and invest in healthcare solutions that address the needs of women. A number of female-centric healthcare apps have been developed, addressing concerns such as infertility, menstrual health, birth control, and sexual wellbeing. Femtech businesses arose as a result of women's lack of access to adequate healthcare. Despite the fact that gender equality is considered a social norm in most industrialized countries, this is not the situation in the rest of the world.

Femtech Market Size US$ 97,317 Mn by 2030
Market Growth Drivers

  • Growing awareness regarding women's health and wellness
  • Surge in use of digital technology to manage women's health
  • Increasing burden of chronic and infectious diseases among women

Market Restraints

  • Lack of awareness for femtech products & services in emerging economies
  • Increasing femtech start-ups leading to a highly competitive market

Market Opportunities

  • Growing investment in the femtech industry
  • Increasing prevalence of women-related disorders

Report Coverage: 

Market Femtech Market
Market Size 2021 US$ 25,291 Mn
Market Forecast 2028 US$ 97,317 Mn
CAGR 16.3% During 2022 - 2030
Analysis Period 2018 - 2030
Base Year 2021
Forecast Data 2022 - 2030
Segments Covered By Type, By End-Use, By Application, And By Geography
Regional Scope North America, Europe, Asia Pacific, Latin America, and Middle East & Africa
Key Companies Profiled Athena Feminine Technologies, Elvie, HeraMED, iSona Health, Totohealth, Minvera, Nuvo, Prelude, Sera Prognostics, Sustain Natural, and Univfy.
Report Coverage
Market Trends, Drivers, Restraints, Competitive Analysis, Player Profiling, Regulation Analysis
Customization Scope

10 hrs of free customization and expert consultation

Market Dynamics

Some of the primary driving aspects of the global femtech market include rising knowledge and acceptance of women's health issues and a surge in the use of digital technology to manage women's health. Until recently, medical research mainly neglected many women's health issues, and women have long been under-represented in clinical trials. Historically, research on women's health focused on disorders affecting fertility and reproduction, whereas many studies on other diseases focused on men. According to the WHO, over 800 women die every day during pregnancy and childbirth, mostly in Sub-Saharan Africa.

Women's technology, like technology for women, is gaining traction. The female-led technology (femtech) industry consists of technology and software companies that are dedicated to meeting the health requirements of women. This expansion has been fueled in part by increasing investment in telehealth and remote monitoring systems during the COVID-19 epidemic.

However, a significant lack of investment in women-led enterprises and women's health is a significant barrier to attaining health fairness. Another issue is the scarcity of women in the technology industry, with only one woman in every five individuals employed in the industry today. The COVID-19 pandemic, which has impacted women's health and economic security globally, has aggravated this. In addition, the lack of awareness of femtech products & services in emerging economies is also limiting the market growth.

On the other hand, the increasing burden of chronic and infectious diseases is fueling the femtech market growth. According to the International Diabetes Foundation, diabetes affects around 537 million persons aged 20 to 79. The total number of diabetics is expected to climb to 643 million by 2030 and 783 million by 2045. Among them, women also held a significant share in this period. Then again, menstrual irregularities occur in an estimated 14% to 25% of women of childbearing age. In addition to that, the leading cause of women’s death is heart disease, cancer, and COVID-19. All these aspects are triggering numerous start-ups and collaborations to support women’s health and serve them with immediate medical attention.

Market Segmentation

The global femtech market is segmented based on type, end-use, application, and geography.

Market By Type

  • Software
  • Product
  • Services

Among them, the product type segment accounted for a significant market share in 2021. Government initiatives to raise awareness about women's health, as well as advanced technical options for precise treatment, will drive market growth. Major healthcare players are stressing the creation of a product pipeline through the use of digital technology. Furthermore, growing companies are heavily spending on R&D to create unique products that would provide better solutions to women. However, the software segment is anticipated to attain a considerable growth rate during the forecast period 2022 – 2030.

Market By End-Use

  • Surgical Centers
  • Fertility Clinics
  • Direct-to-Consumer
  • Hospitals
  • Diagnostic Centers
  • Others

Based on end-use, the diagnostic centers segment is expected to register a significant growth rate throughout the forecast period 2022 – 2030. This is credited to the rising patient inflow prone to several diseases. Specialty diagnosis options for chronic and infectious disorders are available at diagnostic facilities. The introduction of digital health, particularly telehealth systems, has sped up the patient care process. This has allowed a reduction in patient visits, even during the pandemic.

Market By Application

  • Pelvic & Uterine Healthcare
  • Pregnancy & Nursing Care
  • Reproductive Health
  • General Healthcare & Wellness
  • Others

Among all of them, the reproductive health segment is likely to attain a noteworthy CAGR in the coming years. There are several common reproductive health concerns for women such as endometriosis, gynecologic cancer, uterine fibroids, interstitial cystitis, HIV/AIDS, and polycystic ovary syndrome (PCOS) among others. Many initiatives are undertaken by world organizations such as the WHO, CDC, Department of Health (Australia), and UNFPA to support and create awareness of women’s reproductive health concerns, thereby boosting the segmental growth.

Femtech Market Regional Overview

North America

  • U.S.
  • Canada

Europe

  • U.K.
  • Germany
  • France
  • Spain
  • Rest of Europe

Latin America

  • Mexico
  • Brazil
  • Rest of Latin America

Asia-Pacific

  • India
  • Japan
  • China
  • Australia
  • South Korea
  • Rest of Asia-Pacific

Middle East & Africa (MEA)

  • Gulf Cooperation Council (GCC)
  • South Africa
  • Rest of the Middle East & Africa

The growing prevalence of women related diseases in the North America region, fuels the regional market growth

The regional segmentation is given as North America, Latin America, Asia-Pacific, Europe, and the Middle East & Africa. Among all the regions, North America accumulated the largest amount of share in 2021. The surge in prevalence of women-related diseases, high awareness for femtech products & services, and the rising number of menstrual and fertility clinics are all expected to drive the North America femtech market forward. In addition, the Asia-Pacific region is likely to witness the fastest growth rate in the coming years, due to the ongoing investments in the healthcare industry for enhanced treatment facilities. Additionally, the growing number of chronic and infectious disorders in the Asia-Pacific region is also supporting the regional market growth.

Competitive Landscape

Some of the top vendors offered in the professional report include Athena Feminine Technologies, Elvie, HeraMED, iSona Health, Totohealth, Minvera, Nuvo, Prelude, Sera Prognostics, Sustain Natural, and Univfy.

Frequently Asked Questions

How much was the estimated value of the Global Femtech Market in 2021 and projection by 2030?

The estimated value of Global Femtech Market in 2021 was accounted to be US$ 25,291 Mn and market projected to reach US$ 97,317 Mn by 2030

What will be the projected CAGR for Global Femtech Market during forecast period of 2022 to 2030?

The projected CAGR of Global Femtech Market during the analysis period of 2022 to 2030 is 16.3%

Which are the prominent competitors operating in the market?

The prominent players of the global femtech market involve Athena Feminine Technologies, Elvie, HeraMED, iSona Health, Totohealth, Minvera, Nuvo, Prelude, Sera Prognostics, Sustain Natural, and Univfy.

Which region held the dominating position in the global femtech market?

North America held the dominating share for femtech during the analysis period of 2022 to 2030.

Which region exhibited the fastest growing CAGR for the forecast period of 2022 to 2030?

Asia-Pacific region exhibited fastest growing CAGR for femtech during the analysis period of 2022 to 2030.

What are the current trends and dynamics in the global femtech market?

Growing awareness of women's health and wellbeing, an increase in the use of digital technology to manage women's health, and an increase in the burden of chronic and infectious diseases among women all contribute to the expansion of the worldwide femtech market.

By segment type, which sub-segment held the maximum share?

Based on type, product segment held the maximum share for femtech market in 2021.

Select Licence Type

Single User

US$ 4500

Multi User

US$ 7000

Excel Datapack

US$ 2000

Why Acumen Research And Consulting

100%

Customer Satisfaction

24x7

Availability - we are always there when you need us

200+

Fortune 50 Companies trust Acumen Research and Consulting

80%

of our reports are exclusive and first in the industry

100%

more data and analysis

1000+

reports published till date